Clinical leaders’ top concerns about reopening
The key issues to navigate

David Betts, Doug Billings, Natasha Elsner, and Hemnabh Varia

THE DELOITTE CENTER FOR HEALTH SOLUTIONS
As COVID-19 cases recede, we explore how health care organizations can ramp up nonurgent procedures once again—the resources they need, the constraints they face, and the possible timelines for things to come back to pre-COVID-19 levels.

Introduction

The COVID-19 pandemic forced many health care providers to stop performing nonurgent procedures in response to state mandates, to ensure the safety of patients and staff, and to deploy resources toward COVID-19 treatment. Much lower volumes of these procedures have led to a considerable drop in revenue. As COVID-19 cases recede, how are hospitals and health systems going about resuming these procedures?

In May 2020, the Deloitte Center for Health Solutions surveyed clinical leaders to understand their concerns, approaches, and steps toward resuming nonurgent procedures.

METHODOLOGY

Between May 4 and 15, 2020, the Deloitte Center for Health Solutions conducted a short online survey of 50 clinical leaders, including chief medical officers and service line leaders at provider organizations in the United States. These provider organizations included health systems, free-standing hospitals, academic medical centers, and ambulatory surgery centers with an annual revenue of more than US$500 million in the most recent fiscal year.

KEY FINDINGS

The results suggest that resuming nonurgent procedures will be complex, and clinical leaders are preparing for many uncertainties.

TOP CONCERNS INCLUDE A POTENTIAL SECOND OUTBREAK, LOW PATIENT DEMAND, AND SUPPLIES

While health systems have been at the frontline of caring for patients during the epidemic and have received some financial support from federal legislation, the loss of revenue has been a significant financial challenge for many. Surveyed clinical leaders estimate that the nonurgent procedure volume in April 2020 was just 16% of what it was during the same period last year.

When asked to list their top three concerns about resuming deferred procedures, clinical leaders cite the possibility of an outbreak or a second wave as their number one worry (82%), overshadowing all other concerns. Low patient demand due to safety concerns (54%) and adequate supply of materials, medications, equipment or testing (50%) are a distant second, followed by patients’ ability to pay due to loss of income or insurance (40%).
FIGURE 1

The possibility of an outbreak or second wave is the number one concern, followed by low patient demand and adequate supplies

Q: What are your three biggest concerns about resuming deferred elective procedures?

- Possibility of an outbreak or second wave: 82%
- Low patient demand because of safety/infection concerns: 54%
- Adequate supply of materials, medications, equipment, or testing (including trunk stock): 50%
- Patients’ ability to pay due to loss of income and/or loss of insurance coverage: 40%
- Staffing challenges due to illness, redeployment, or refusing to work: 26%
- Overwhelming pent-up demand surge: 24%
- Increased patient acuity as a result of delayed care: 18%
- Staff morale: 2%

Note: Total number of respondents, N=50.
When it comes to supply chain, the top three concerns include testing capabilities (74%), personal protective equipment or PPE (68%), and the availability of medical and surgical supplies other than PPE (58%). These are all areas in which suppliers can support their customers.

Organizations probably have the least control over the possibility of another outbreak or wave. And a large outbreak can have cascading effects on other important variables: patient demand, availability of testing and supplies, and staffing.

Lingering supply chain issues and the possibility of new outbreaks should compel organizations to rethink how they stock, distribute, forecast, and track supplies by site and service line. Providers may have a newfound desire for upstream visibility into the supply chain, whereas suppliers might want a detailed understanding of downstream utilization. This would call for a much closer coordination among supply chain stakeholders: providers, group purchasing organizations (GPOs), distributors, and medtech companies.

ADEQUATE TESTING IS THE KEY CAPABILITY ORGANIZATIONS ARE LOOKING FOR

In response to our question about what capabilities are still lacking, sufficient testing (for the virus and for antibodies) tops the list (figure 3).

While both clinical leaders at organization/system level and leaders at the service line level agree about the lack of testing, their perspectives diverge on three other capabilities:
• **Infection control for operating and procedure rooms:** Only 7% of respondents at the service line level feel this capability still needs strengthening, but a much larger share at the organization/system level (47%) feels this way.

• **Understanding readiness and capacity of other community providers (e.g., referring physicians, diagnostic facilities, post-op rehab/follow-up):** A much larger percentage of service line leaders (60%) than of organization- or system-level leaders (18%) feel they need to strengthen their organizations’ capability in this area.

• **Capabilities to monitor outbreaks:** About 21% of organization-level leaders versus 47% of service line leaders think this is lacking.

**FIGURE 3**

Testing is the number one needed capability for resuming deferred procedures

Q: What, if any, capabilities and resources do you feel your organization still needs to strengthen, in order to resume deferred procedures?

- **Testing (for COVID-19 and antibodies):** 76%
- **Infection control measures for ORs/procedure rooms:** 35%
- **Understanding readiness and capacity of other community providers (e.g., referring physicians, diagnostic facilities, post-op rehab/follow-up):** 31%
- **Capabilities to monitor outbreaks:** 29%
- **Tools and capabilities to maximize OR utilization and throughput:** 27%
- **Forecasting and tracking inventory:** 27%
- **Data on consumer sentiment/preferences:** 24%
- **Streamlined patient and resource scheduling:** 18%
- **Operating capital/liquidity:** 16%
- **Automated/streamlined benefit verification:** 12%
- **Enhanced cybersecurity:** 6%

Note: N=49.
These differences may be due to different exposure to what is happening at various levels of the organization or multiple locations, or due to the differences in tactical vs. strategic understanding of what is needed.

ORGANIZATIONS ARE TRYING TO MITIGATE CONSUMER CONCERNS THROUGH VIRTUAL HEALTH PRACTICES AND COMMUNICATION

To mitigate concerns associated with resuming deferred procedures, clinical leaders say their organizations are putting in place a number of measures (figure 4).

- Almost everybody (98%) in our survey says their organizations have implemented or plan to implement virtual health practices for some or all nonprocedural visits.

This represents a major shift in practice: the Deloitte 2020 Survey of US Physicians, conducted in January–February 2020 before the COVID-19 pandemic, showed that only 14% of surgical specialists had video visit capabilities and of those who had, a third (34%) were using them. This amounts to just 5% of all surgical specialists having experience with video visits before COVID-19.

- Nearly all respondents (96%) say their organizations have developed or plan to develop an external communication strategy.

However, measuring consumer sentiment is the least common activity being implemented (36%) according to our survey. Consumer perceptions are likely to affect demand for procedures, which 54% of our respondents noted (figure 1). Individuals who need nonurgent procedures tend to be older than the general population (57 vs. 38 years old, on average) and by some estimates more than three in five have at least one comorbidity, putting them at a higher risk of severe illness from COVID-19. These consumers may be especially worried about getting their procedures done while the epidemic continues. Health systems should allay consumers’ concerns by tailoring their communications and showing they are able to minimize the spread of infection through adequate PPE for staff and patients and robust infection control.

We expect consumer attitudes and behaviors to be increasingly important for reopening. Organizations should establish market-sensing capabilities to monitor consumer sentiment by key psychographic segments and geographies. These efforts could focus on consumer confidence (including financial outlook, job security, capacity of the health care system), perceptions of safety, and types of services consumers are cancelling or delaying. They could use multiple data inputs and analytical approaches for the purpose—from survey research to social media to internal information on appointment scheduling and testing.
FIGURE 4

Survey respondents say they are planning or implementing many steps to prepare for the immediate future

Q: What steps has your organization taken or plans to take to mitigate these concerns?

<table>
<thead>
<tr>
<th>Steps</th>
<th>Partially or fully implemented</th>
<th>Planning</th>
<th>Not considering</th>
<th>Don’t know</th>
</tr>
</thead>
<tbody>
<tr>
<td>Consumers</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Develop external communications strategy</td>
<td>70%</td>
<td>26%</td>
<td>4%</td>
<td>0%</td>
</tr>
<tr>
<td>Measure consumer sentiment (e.g., surveys, analysis of social media, or call center data)</td>
<td>36%</td>
<td>46%</td>
<td>16%</td>
<td>2%</td>
</tr>
<tr>
<td>Workforce</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Develop internal communications strategy</td>
<td>92%</td>
<td>8%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>Provide support and tools to help employees cope</td>
<td>84%</td>
<td>14%</td>
<td>2%</td>
<td>0%</td>
</tr>
<tr>
<td>Employee surveys and town halls</td>
<td>50%</td>
<td>40%</td>
<td>8%</td>
<td>2%</td>
</tr>
<tr>
<td>Operations/supply chain</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acquisition of PPE</td>
<td>94%</td>
<td>6%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>Additional cleaning and disinfecting measures</td>
<td>88%</td>
<td>12%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>Use telehealth for some or all nonprocedural visits</td>
<td>88%</td>
<td>10%</td>
<td>2%</td>
<td>0%</td>
</tr>
<tr>
<td>Working with suppliers to ensure availability of drugs and supplies</td>
<td>86%</td>
<td>12%</td>
<td>0%</td>
<td>2%</td>
</tr>
<tr>
<td>Train/retrain staff on infection control procedures</td>
<td>80%</td>
<td>18%</td>
<td>2%</td>
<td>0%</td>
</tr>
<tr>
<td>Financial and tax</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scenario planning</td>
<td>70%</td>
<td>24%</td>
<td>0%</td>
<td>6%</td>
</tr>
<tr>
<td>Evaluating funding resources from government stimulus programs</td>
<td>66%</td>
<td>28%</td>
<td>2%</td>
<td>4%</td>
</tr>
</tbody>
</table>

Note: N=50.
PREPLANNING AND EXTENDED HOURS ARE THE TOP CHOICES FOR DEALING WITH POTENTIAL DEMAND SURGES
We explored measures being put in place to maximize patient throughput and utilization of operating rooms should there be surges in procedure demand. Surgical preplanning and extending hours of operation are the most common approaches planned or implemented. A quarter of the respondents are not considering approaches to simplify and/or reduce provider preferences, though doing so could help streamline patient scheduling.

Changes to operating hours and scheduling could have implications for external stakeholders such as suppliers, community providers, or medical transport companies, who might need to adjust their practices to help health systems to maximize their capacity.

Even without demand surges, large expenses for treating COVID patients, new and more time-consuming infection control measures, and potential erosion in the payer mix are putting pressure on many organizations to seek efficiencies.

FIGURE 5
Top three measures to maximize OR utilization in anticipation of surges in demand
Surgical preplanning, extending hours for operating rooms, and simplifying provider preferences in scheduling
Q: In preparation for possible surges in procedure demand, what measures has your organization taken to maximize OR/procedure room utilization and patient throughput?

<table>
<thead>
<tr>
<th>Partially or fully implemented</th>
<th>Planning</th>
<th>Not considering</th>
<th>Don’t know</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgical preplanning</td>
<td>62%</td>
<td>38%</td>
<td></td>
</tr>
<tr>
<td>Extended hours for operating OR/procedure rooms</td>
<td>39%</td>
<td>56%</td>
<td>4%</td>
</tr>
<tr>
<td>Simplify/reduce provider preferences in scheduling</td>
<td>42%</td>
<td>30%</td>
<td>26%</td>
</tr>
<tr>
<td>Bed planning software that predicts demand for inpatient beds (for procedures requiring inpatient stay)</td>
<td>26%</td>
<td>20%</td>
<td>44%</td>
</tr>
<tr>
<td>Scheduling software that predicts demand and matches staffing and resources accordingly</td>
<td>22%</td>
<td>18%</td>
<td>50%</td>
</tr>
<tr>
<td>Shortened surgery time</td>
<td>14%</td>
<td>24%</td>
<td>62%</td>
</tr>
<tr>
<td>Engaging third parties like medtech consultants to help find opportunities for efficiencies</td>
<td>8%</td>
<td>8%</td>
<td>76%</td>
</tr>
</tbody>
</table>

Note: N=50.
Surveyed clinical leaders expect the return to pre-COVID-19 productivity volumes to take two to six months, with three months being the typical (median) estimate. This relatively optimistic estimate may reflect respondents’ confidence in their organizations’ ability to prepare for reopening.

However, organizations will need to overcome significant operational challenges to reach pre-pandemic productivity. New protocols to minimize infection risk can create inefficiencies and constrain health care systems’ ability to operate at the same capacity as before. Patient scheduling can become more complicated and additional pre-operative testing for the virus and screening patients and staff for symptoms can increase same-day cancellations. Social distancing requirements could mean fewer patients and lower daily caseloads, and additional cleaning and infection controls may slow down room turnover, impacting throughput. It could also mean minimal presence of medical device company representatives or other nonstaff services surgeons rely on to ensure efficiency in their operating rooms.

**Conclusion**

Resuming nonurgent procedures may be more complicated and take longer than expected. While everybody is anxious to reopen, the approach should be methodical and allow for contingencies against possible risks to determine when to open, what services to resume, and how to reboot revenue while building resiliency in the system and keeping the patient and the community at the center. Such resiliency will likely require a real-time view of data on consumer sentiment and behavior, the pace and progression of testing, readiness of the clinical and nonclinical workforce, having the operational procedures in place to compartmentalize COVID-19 and non-COVID-19 care, and the financial resiliency to withstand the challenges that organizations may face as they ramp up operations again.
Clinical leaders’ top concerns about reopening: The key issues to navigate

Endnotes


Acknowledgments

Project team: Wendy Gerhardt championed the research concept, ensured timely project execution, and helped edit the paper. Sonal Shah provided support with questionnaire development and interpretation of the findings.

The authors would like to thank Glenn Snyder, Randy Gordon, Kulleni Gebreyes, Claire Boozer Cruse, Jane Makhoul, Sally Bogus, Courtney Burton, Sarah Thomas, Leena Gupta, Pedro Arboleda, Jay Zhu, Laura DeSimio, Ramani Moses, and the many others who contributed their ideas and insights to this project.
About the authors

David Betts | dabetts@deloitte.com

David Betts is a principal in Deloitte Consulting LLP's Life Sciences and Health Care practice. He leads Deloitte's customer transformation initiatives for the health care provider sector, and his work has focused on enhancing core operations in the revenue cycle, driving performance improvement through operating model transformation and growing the business through mergers and acquisitions, all with an eye toward creating a more patient-centric, consumer-oriented delivery system.

Doug Billings | dbillings@deloitte.com

Doug Billings leads the MedTech Innovation, Product Development, and R&D practice within Deloitte. He has more than 30 years of experience in medical device innovation, product strategy, product development, operational scale-up, and merger integration. He has successfully worked in and with multinational corporations and technology startups to help them successfully conceive, create, and commercialize market leading products and solutions. Billings has a degree in biology from Duke University and an MBA from Ross School of Business at the University of Michigan.

Natasha Elsner | nelsner@deloitte.com

Natasha Elsner is a research manager with the Deloitte Center for Health Solutions. She has spent more than 10 years in market research serving health care clients. With extensive experience in research methodology and data analysis, Natasha conducts cross-sector research at the Center. Natasha holds a master's degree in survey research and methodology.

Hemnabh Varia | hvaria@deloitte.com

Hemnabh Varia is a senior analyst with Deloitte Services India Pvt Ltd, affiliated with the Deloitte Center for Health Solutions. He has more than seven years of experience in market research, competitive intelligence, financial analysis, and research report writing. Varia holds a master's degree in business administration from Mumbai University.
Contact us

*Our insights can help you take advantage of change. If you're looking for fresh ideas to address your challenges, we should talk.*

**Industry leadership**

**David Betts**  
Principal | Deloitte Consulting LLP  
+ 1 412 402 5967 | dabetts@deloitte.com  

David Betts is a principal in Deloitte Consulting LLP’s Life Sciences and Health Care practice and leads Deloitte’s customer transformation initiatives for the health care provider sector. He is based in Pittsburgh.

**Doug Billings**  
Managing director | Deloitte Consulting LLP  
+ 1 617 449 5149 | dbillings@deloitte.com  

Doug Billings leads the MedTech Innovation, Product Development and R&D practice within Deloitte. He is based in Boston.

**The Deloitte Center for Health Solutions**

**Sarah Thomas, MS**  
Managing director | Deloitte Services LP  
+ 1 202 220 2749 | sarthomas@deloitte.com  

Sarah Thomas is the managing director of the Deloitte Center for Health Solutions. Her role involves driving the center research agenda to inform stakeholders across the health care landscape about key issues and trends facing the industry.
About the Deloitte Center for Health Solutions

The source for health care insights: The Deloitte Center for Health Solutions (DCHS) is the research division of Deloitte LLP’s Life Sciences and Health Care practice. The goal of DCHS is to inform stakeholders across the health care system about emerging trends, challenges, and opportunities. Using primary research and rigorous analysis, and providing unique perspectives, DCHS seeks to be a trusted source for relevant, timely, and reliable insights.

Connect
To learn more about the DCHS and our research, please visit www.deloitte.com/us/centerforhealthsolutions.

COVID-19 RESPONSE CAPABILITIES FOR HEALTH CARE ORGANIZATIONS: RAPIDLY COMBATING COVID-19 WITH RESILIENCE

The COVID-19 pandemic has caused health care organizations to adjust to clinical resource and financial challenges that would have previously been unthinkable. Where can your organization focus its response? And what should you do next?

Learn how we can help you combat the coronavirus with resilience.
About Deloitte Insights

Deloitte Insights publishes original articles, reports and periodicals that provide insights for businesses, the public sector and NGOs. Our goal is to draw upon research and experience from throughout our professional services organization, and that of coauthors in academia and business, to advance the conversation on a broad spectrum of topics of interest to executives and government leaders. Deloitte Insights is an imprint of Deloitte Development LLC.

About this publication

This publication contains general information only, and none of Deloitte Touche Tohmatsu Limited, its member firms, or their affiliates are, by means of this publication, rendering accounting, business, financial, investment, legal, tax, or other professional advice or services. This publication is not a substitute for such professional advice or services, nor should it be used as a basis for any decision or action that may affect your finances or your business. Before making any decision or taking any action that may affect your finances or your business, you should consult a qualified professional adviser. None of Deloitte Touche Tohmatsu Limited, its member firms, or its and their respective affiliates shall be responsible for any loss whatsoever sustained by any person who relies on this publication.

About Deloitte

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as “Deloitte Global”) does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the “Deloitte” name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.

Copyright © 2020 Deloitte Development LLC. All rights reserved.
Member of Deloitte Touche Tohmatsu Limited